China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Classical Hodgkin’s Lymphoma Who Have Received at Least Two Prior Therapies

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment